Follow
Konstantin Byrgazov
Konstantin Byrgazov
Oncopeptides AB
Verified email at oncopeptides.com
Title
Cited by
Cited by
Year
Selective translation of leaderless mRNAs by specialized ribosomes generated by MazF in Escherichia coli
O Vesper, S Amitai, M Belitsky, K Byrgazov, AC Kaberdina, ...
Cell 147 (1), 147-157, 2011
3232011
Ribosome heterogeneity: another level of complexity in bacterial translation regulation
K Byrgazov, O Vesper, I Moll
Current opinion in microbiology 16 (2), 133-139, 2013
1012013
Structural basis for the interaction of protein S1 with the Escherichia coli ribosome
K Byrgazov, I Grishkovskaya, S Arenz, N Coudevylle, H Temmel, ...
Nucleic Acids Research 43 (1), 661-673, 2015
592015
The MazF-regulon: a toolbox for the post-transcriptional stress response in Escherichia coli
M Sauert, MT Wolfinger, O Vesper, C Müller, K Byrgazov, I Moll
Nucleic Acids Research 44 (14), 6660-6675, 2016
562016
Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
G Heller, T Topakian, C Altenberger, S Cerny-Reiterer, S Herndlhofer, ...
Leukemia 30 (9), 1861-1868, 2016
552016
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
KV Gleixner, M Schneeweiss, G Eisenwort, D Berger, H Herrmann, K Blatt, ...
Haematologica 102 (9), 1519, 2017
352017
Direct interaction of the N-terminal domain of ribosomal protein S1 with protein S2 in Escherichia coli
K Byrgazov, S Manoharadas, AC Kaberdina, O Vesper, I Moll
PLoS One 7 (3), e32702, 2012
262012
Block synthesis of blood group tetrasaccharides B (types 1, 3 and 4)
EY Korchagina, IM Ryzhov, KA Byrgazov, IS Popova, SN Pokrovsky, ...
Mendeleev Communications 19 (3), 152-154, 2009
252009
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
K Byrgazov, CB Lucini, P Valent, O Hantschel, T Lion
Haematologica 103 (1), e10, 2018
182018
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
K Byrgazov, R Kastner, M Gorna, G Hoermann, M Koenig, CB Lucini, ...
Leukemia 31 (1), 237-240, 2017
112017
Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
K Byrgazov, CB Lucini, B Berkowitsch, M Koenig, OA Haas, G Hoermann, ...
Oncotarget 7 (47), 78083, 2016
112016
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
K Byrgazov, C Anderson, B Salzer, E Bozsaky, R Larsson, J Gullbo, ...
Therapeutic Advances in Medical Oncology 12, 1758835920937891, 2020
82020
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML
M Schneeweiss-Gleixner, K Byrgazov, G Stefanzl, D Berger, G Eisenwort, ...
EBioMedicine 50, 111-121, 2019
72019
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations
KV Gleixner, Y Filik, D Berger, C Schewzik, G Stefanzl, I Sadovnik, ...
American Journal of Cancer Research 11 (9), 4470, 2021
62021
A novel fusion gene NDEL1-Pdgfrb in a patient with JMML with a new variant of TKI-resistant mutation in the kinase domain of PDGFRβ
K Byrgazov, R Kastner, M Dworzak, G Hoermann, OA Haas, R Ulreich, ...
Blood 124 (21), 613, 2014
62014
A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML
KV Gleixner, I Sadovnik, M Schneeweiss, G Eisenwort, K Byrgazov, ...
Leukemia research 78, 36-44, 2019
42019
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
K Byrgazov, M Kraus, A Besse, A Slipicevic, F Lehmann, C Driessen, ...
Leukemia research 101, 106499, 2021
32021
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
K Byrgazov, A Besse, M Kraus, A Slipicevic, F Lehmann, C Driessen, ...
HemaSphere 5 (7), 2021
12021
A peptidase-potentiated alkylating agent melflufen is effective anti-neoplastic agent in osteosarcoma
K Byrgazov, A Slipicevic, F Lehmann, T Lion, L Kager, S Taschner-Mandl
Annals of Oncology 30, v706, 2019
12019
Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml
KV Gleixner, MA Schneeweiss, H Herrmann, K Blatt, D Berger, ...
Blood 128 (22), 4241, 2016
12016
The system can't perform the operation now. Try again later.
Articles 1–20